Effectiveness of lurasidone in schizophrenia or schizoaffective patients switched from other antipsychotics: a 6-month, open-label, extension study. - Wikidata - wikimedia - TriplyDB

Effectiveness of lurasidone in schizophrenia or schizoaffective patients switched from other antipsychotics: a 6-month, open-label, extension study.

Effectiveness of lurasidone in schizophrenia or schizoaffective patients switched from other antipsychotics: a 6-month, open-label, extension study.

http://www.wikidata.org/entity/Q34073723

about

Schizophrenia relapse, patient considerations, and potential role of lurasidone Lurasidone for the treatment of bipolar depression: an evidence-based review An evaluation of the effects of the novel antipsychotic drug lurasidone on glucose tolerance and insulin resistance: a comparison with olanzapine The clinical utility of lurasidone in schizophrenia: patient considerations Weight change during long-term treatment with lurasidone: pooled analysis of studies in patients with schizophrenia.LURASIDONE IN THE LONG-TERM TREATMENT OF PATIENTS WITH BIPOLAR DISORDER: A 24-WEEK OPEN-LABEL EXTENSION STUDY Long-term health-related quality of life improvements among patients treated with lurasidone: results from the open-label extension of a switch trial in schizophrenia.An update of safety of clinically used atypical antipsychotics.Lurasidone: a novel antipsychotic agent for the treatment of schizophrenia and bipolar depression.A double-blind, placebo-controlled, randomized withdrawal study of lurasidone for the maintenance of efficacy in patients with schizophrenia.A 6-week, double-blind, placebo- and haloperidol-controlled, phase II study of lurasidone in patients with acute schizophrenia.Investigational drugs for anxiety in patients with schizophrenia.Lurasidone in the treatment of schizophrenia: a critical evaluation.Weight changes before and after lurasidone treatment: a real-world analysis using electronic health records.Current and potential pharmacological and psychosocial interventions for anxiety symptoms and disorders in patients with schizophrenia: structured review.Lurasidone: efficacy and safety in the treatment of psychotic and mood disorders.The Black Book of Psychotropic Dosing and Monitoring.A long-Term, Open-Label Study to Evaluate the Safety and Tolerability of Brexpiprazole as Maintenance Treatment in Adults with Schizophrenia.A prospective year-long follow-up of lurasidone use in clinical practice: factors predicting treatment persistence.

P2860

Q26738850-329A07D0-3754-456D-8D1D-5DDB165EAC7C Q26796437-D764B2AB-C8B4-410D-B5C2-036242033E57 Q28543222-EEEC5BAD-20D9-4B55-B6C2-99B0131FCA62 Q34477219-11FFB7B5-89A8-404E-8CD9-55E98D36F4DE Q34486175-F445B1CE-3127-4B81-B201-E60F63D67B4C Q34515834-180DB54A-AB47-4EA7-B8E8-9FEE8D40AEF3 Q36035382-6104F915-4D3A-4F6F-9B99-6070C7BE3E30 Q36062184-E7ED2780-97FB-49CD-9F96-A3432B928B8D Q36444832-E1DE0F8D-8C25-407D-A07A-C3A3DF74C086 Q36475355-0D9B45C3-8394-4188-B8A7-53D85CBAA05B Q36489406-79720901-45A6-4B5C-8EA0-60EF212E550D Q38271298-FE683093-D9A3-4A28-8494-12761B8AC37A Q38537910-0CD7B43E-DE57-4DE2-8C74-E5B36C87F0CA Q42682470-8ACE40CB-4614-4A96-8C59-9CB2C993DDB1 Q46365588-5C833900-F9E0-47FF-9FE0-99A8A7719B44 Q47623090-2950AC44-8BAD-4A87-B47A-694DFB954C86 Q47642128-D74E50D0-0846-4A99-AC52-63A4FEC1EF9B Q50132603-F7C56303-EF75-492F-AA9E-6DAB0932DA67 Q55304752-78B78A6C-5F7E-41CF-AC63-5B7BF37B27BD

P2860

Effectiveness of lurasidone in schizophrenia or schizoaffective patients switched from other antipsychotics: a 6-month, open-label, extension study.

http://www.wikidata.org/entity/Q34073723

description

2013 nî lūn-bûn

@nan

2013 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Effectiveness of lurasidone in ...... , open-label, extension study.

@ast

Effectiveness of lurasidone in ...... , open-label, extension study.

@en

Effectiveness of lurasidone in ...... , open-label, extension study.

@nl

type

label

Effectiveness of lurasidone in ...... , open-label, extension study.

@ast

Effectiveness of lurasidone in ...... , open-label, extension study.

@en

Effectiveness of lurasidone in ...... , open-label, extension study.

@nl

prefLabel

Effectiveness of lurasidone in ...... , open-label, extension study.

@ast

Effectiveness of lurasidone in ...... , open-label, extension study.

@en

Effectiveness of lurasidone in ...... , open-label, extension study.

@nl

P1433

Q34073723-F2E9F1B6-0310-49DE-95AA-487093A8D0C1

P1476

Q34073723-BE0B4207-A39B-4439-A283-BCDF427B3921

P2093

Q34073723-0A66352D-FCC1-4EAF-B761-04E10E685FF9

Q34073723-2A5B9EBA-442D-43D7-8FEF-825C7C05CE92

Q34073723-7DA574C4-B8A0-4FAA-9FD5-DC2F8B15A4BC

Q34073723-8EFF5AAE-0D1F-42A7-AD43-CDF5E5995418

Q34073723-C73C6EB9-1B29-4D9D-8C70-03E7226CD4E0

Q34073723-CF8A5DD2-5FB4-49C4-B68F-95EE9138C6B1

P2860

Q34073723-162C55E8-6C5E-4318-AF33-8BFBA7BE1610

Q34073723-172E3AEA-E02B-4EBE-B518-DAADCE666CF2

Q34073723-1D52BE28-B758-46FC-8A88-90F3475717EB

Q34073723-407B6AEC-F0C7-4E1F-9B91-EA6280888CD0

Q34073723-4DF13D33-9801-4F75-AEFF-8D4F706C948D

Q34073723-4FD36C17-E60C-4714-B3CD-139087FDF320

Q34073723-5B747B0C-C932-4E92-BC2B-3DFECBDA8FC0

Q34073723-5BE76419-3E76-496A-A7B0-142BBD89E146

Q34073723-5FDFEF78-6A1E-459F-9916-180C3078E4BE

Q34073723-7A50E061-72C6-40F6-8884-7DF7566FC708

P304

Q34073723-A75AEFED-5D21-4447-8B99-EC54C8366EA9

P31

Q34073723-D74FF382-B985-4A08-8085-0CED693E3841

P356

Q34073723-BA441EF7-E086-49A5-825A-95ECE475C94B

P433

Q34073723-752150A1-3B5B-411F-A529-DD0992743B92

P478

Q34073723-F095DCF7-0F7A-446C-8751-A4F776371AE8

P50

Q34073723-B2044CC5-2512-41E4-8B32-803E0ED3D746

P577

Q34073723-03470136-8F58-497A-922F-8102527A4C01

P698

Q34073723-9F145A98-C1B5-49F0-8D63-4E665BE885C1

P921

Q34073723-B427B884-4895-42C9-A66B-C3AB32268F84

P932

Q34073723-4365A783-F52C-4871-94F4-44517B5C25B9

P356

S109285291300093X

P1433

C N S Spectrums

P1476

Effectiveness of lurasidone in ...... , open-label, extension study.

@en

P2093

Antony Loebel

http://www.w3.org/2001/XMLSchema#string

Christoph U Correll

http://www.w3.org/2001/XMLSchema#string

Jay Hsu

http://www.w3.org/2001/XMLSchema#string

Joseph P McEvoy

http://www.w3.org/2001/XMLSchema#string

Josephine Cucchiaro

http://www.w3.org/2001/XMLSchema#string

Peter J Weiden

http://www.w3.org/2001/XMLSchema#string

P2860

A rating scale for drug-induced akathisia

Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis

A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity

Clinical and economic ramifications of switching antipsychotics in the treatment of schizophrenia

The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults.

Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder: a systematic review and exploratory meta-analysis.

Past and present progress in the pharmacologic treatment of schizophrenia.

Lurasidone in the treatment of schizophrenia: a 6-week, placebo-controlled study.

Switching in the era of atypical antipsychotics. An updated review.

Switching antipsychotics as a treatment strategy for antipsychotic-induced weight gain and dyslipidemia.

P304

330-339

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1017/S109285291300093X

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

19

http://www.w3.org/2001/XMLSchema#string

P50

P577

2013-12-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24330868

http://www.w3.org/2001/XMLSchema#string

P921

P932

4140225

http://www.w3.org/2001/XMLSchema#string